Supramolecular dynamics of thalidomide and its derivatives in water-sediment system

Chirality

Volumn 22, Issue 4, 2010, Pages 416-424

  Ali, Imran ^a   Gupta, Vinod K ^b,c   Aboul Enein, Hassan Y ^d,e  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY ROORKEE   (India)

^c KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS   (Saudi Arabia)

^d NATIONAL RESEARCH CENTRE   (Egypt)

^e UNIVERSITI TEKNOLOGI MALAYSIA   (Malaysia)

Author keywords

Chiral separations; Supramolecular chiral dynamics; Thalidomide; Water sediment system

Indexed keywords

3 BUTYLTHALIDOMIDE; 3 ETHYLTHALIDOMIDE; 3 METHYLTHALIDOMIDE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHIRALITY; DRUG DETERMINATION; ENANTIOMER; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SEDIMENT; SOLID PHASE EXTRACTION; STEREOCHEMISTRY; SUPRAMOLECULAR CHEMISTRY; TEMPERATURE DEPENDENCE; WATER CONTAMINATION;

ADSORPTION; CHEMISTRY TECHNIQUES, ANALYTICAL; CHROMATOGRAPHY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ETHANOL; HYDROGEN-ION CONCENTRATION; KINETICS; MAGNESIUM SILICATES; MODELS, CHEMICAL; SODIUM; STEREOISOMERISM; THALIDOMIDE; THERMODYNAMICS; TIME FACTORS; WATER;

EID: 77950433636     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20757     Document Type: Article

References (28)

1. McBride W. Thalidomide and congenital abnormalities. Lancet 1961;2:1398-1400.
2. Mellin G, Katzenstein MN. The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 1962;267:1184-1193.
3. Blaschke G, Kraft HP, Fickentscher K, Köhler F. Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers. Arzneimittel Forsch.( Drug Res.) 1979;29:1640-1642.
4. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001;57:365-376.
5. Sleijfer S, Kruit WH, Stoter G. Thalidomide in solid tumours: the resurrection of an old drug. Eur J Cancer 2004;40:2377-2382.
6. Jakeman P, Smith WCS. Thalidomide in leprosy reaction. Lancet 1994;343:432-433.
7. Shimazawa R, Miyachi H, Takayama H, Kuroda K, Kato F, Kato M, Hashimoto Y. Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide. Biol Pharm Bull 1999;22:224-226.
8. Makonkawkeyoons S, Limson-Pobre RNR, Moreira AL, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:5974-5978.
9. Chuong PH, Galons H, Voisin J, Righenzi S, Warnet JM, Claude JR, Huynh-Thien D. In vitro and in vivo immunosuppressive potential of thalidomide and its derivative, N-hydroxythalidomide, alone and in combination with cyclosporin A. Int J Immunopharmacol 1997;19:289-296.
10. Bernstein JR. Thalidomide. Clin Toxicol Rev 1999;21:5.
11. Georghiou PR, Allworth AM. Pasteurella multocida infection after a Tasmanian devil bite. Clin J Infect Dis 1992;166:939-940.
12. Gunzler V. Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations. Drug Saf 1992;7:116-134.
13. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR, Santos GN. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055-1058.
14. Youle M, Clarbour J, Farthing C, Connolly M, Hawkins D, Staughton R, Gazzard B. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Br Med J 1989;298:432-436.
15. Testa B, Carrupt PA, Gal J. The so-called interconversion of stereoisomeric drugs: an attempt at clarification. Chirality 1993;5:105-111.
16. Knoche B, Blaschke G. Investigations on the in vitro racemization of thalidomide by high-performance liquid chromatography. J Chromatogr A 1994;666:235-240.
17. Knoche B, Blaschke G. Stereoelectivity of the in vitro metabolism of thalidomide. Chirality 1994;6:221-224.
18. Eriksson T, Bjrkman S, Roth B, Fyge A, Hglund P. Stereospecific determination, chiral inversion in vitro and pharmakokinetics in humans of the enantiomers of thalidomide. Chirality 1995;7:44-52.
19. Weinz C, Blaschke G. Investigation of the in vitro biotransformation and simultaneous enantioselective separation of thalidomide and its neutral metabolites by capillary electrophoresis. J Chromatogr B 1995;647:287-292.
20. Eriksson T, Bjorkman S, Roth B, Fyge A, Hoglun P. Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality 1998;10:223-228.
21. Reist M, Carrupt PA, Francotte E, Testa B. Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin and chiral stability of teratogenic metabolites. Chem Res Toxicol 1998;11:1521-1528.
22. Meyring M, Mhlenbrock C, Blaschke G. Investigation of the stereoselective in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis. Electrophoresis 2000;21:3270-3279.
23. Gupta VK, Ali I. Removal of endosulfan and methoxychlor from water on carbon slurry. Environ Sci Technol 2008;42:766-770.
24. Gupta VK, Ali I, Saini VK. Removal of chlorophenols from wastewater using red mud: an aluminum industry waste. Environ Sci Technol 2004;38:4012-4018.
25. Reichenberg D. Properties of ion exchange resins in relation to their structure. III. Kinetics of exchange. J Am Chem Soc 1953;75:589-597.
26. Trapp O, Schoetz G. Schurig V. Stereointegrity of thalidomide: gas chromatographic determination of the enantiomerization barrier. J Pharam Biomed Anal 2002;27:497-505.
27. Schoetz G, Trapp O. Schurig V. Determination of the enantiomerization barrier of thalidomide by dynamic elelctrokinetic chromatograpphy. Electrophoresis 2001;22:3185-3190.
28. Trapp O. The unified equation for the evaluation of degenerated frist order reactions in dynamic electrophoresis. Electrophoresis 2006;27: 2999-3006.